Lv1
50 积分 2021-10-18 加入
Thrombopoietin receptor agonist and rituximab combination therapy in patients with refractory primary immune thrombocytopenia
22小时前
已完结
Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world
2个月前
已完结
Eltrombopag (thrombopoietin‐receptor agonist) and plasmapheresis as rescue therapy of acute post‐renal transplant immune thrombocytopenia in a child with Schimke immuno‐osseous dysplasia—case report
2个月前
已完结
Multiple myeloma
4个月前
已完结
Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?
4个月前
已完结
Immunomodulation of immunothrombocytopenia
4个月前
已完结
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study
4个月前
已完结
Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis
4个月前
已完结
Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
4个月前
已完结
Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
7个月前
已完结
皖公网安备34019202002308
